| Literature DB >> 21743439 |
Pelagia Deriziotis1, Ralph André, David M Smith, Rob Goold, Kerri J Kinghorn, Mark Kristiansen, James A Nathan, Rina Rosenzweig, Dasha Krutauz, Michael H Glickman, John Collinge, Alfred L Goldberg, Sarah J Tabrizi.
Abstract
Prion diseases are associated with the conversion of cellular prion protein (PrP(C)) to toxic β-sheet isoforms (PrP(Sc)), which are reported to inhibit the ubiquitin-proteasome system (UPS). Accordingly, UPS substrates accumulate in prion-infected mouse brains, suggesting impairment of the 26S proteasome. A direct interaction between its 20S core particle and PrP isoforms was demonstrated by immunoprecipitation. β-PrP aggregates associated with the 20S particle, but did not impede binding of the PA26 complex, suggesting that the aggregates do not bind to its ends. Aggregated β-PrP reduced the 20S proteasome's basal peptidase activity, and the enhanced activity induced by C-terminal peptides from the 19S ATPases or by the 19S regulator itself, including when stimulated by polyubiquitin conjugates. However, the 20S proteasome was not inhibited when the gate in the α-ring was open due to a truncation mutation or by association with PA26/PA28. These PrP aggregates inhibit by stabilising the closed conformation of the substrate entry channel. A similar inhibition of substrate entry into the proteasome may occur in other neurodegenerative diseases where misfolded β-sheet-rich proteins accumulate.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21743439 PMCID: PMC3160194 DOI: 10.1038/emboj.2011.224
Source DB: PubMed Journal: EMBO J ISSN: 0261-4189 Impact factor: 11.598